Danielle Mroz

Patients with rheumatoid arthritis who had inadequate response to previous biologic disease-modifying antirheumatic drugs found greater pain relief when taking 2 mg or 4 mg of baricitinib compared with placebo.

Eric M. Ruderman, MD, addresses adverse events and toxicities in patients taking disease-modifying antirheumatic drugs (DMARDs).

Patients with active rheumatoid arthritis who are cs/bDMARD-naïve may see a greater reduction in pain and improvement in physical function on baricitinib monotherapy compared with monotherapy of tocilizumab or adalimumab.

Periods of moderate-to-vigorous intensity walking (instead of non-walking) was associated with less risk of total knee replacement over 5 years in patients who have, or who are at high risk of, osteoarthritis of the knee.

The following medications were decreased most frequently and also associated with the greatest impact in terms of reduction of annual cost: adalimumab, etanercept, and rituximab.